Adaptos® requires CE certification and for that, Adaptos® is now evaluated in clinical investigation. Biomendex chose Aurevia (then Labquality) as their CRO partner for their randomized, controlled, multi-center clinical investigation to evaluate Adaptos® Ortho Wedge Bone Graft Substitute, indicated for high tibial osteotomy, a procedure for correcting knee malalignment.
The development of a high-risk class implantable medical device within a heavily regulated environment inevitably presents challenges for the project. Aurevia is working on clinical evaluation, monitoring, data management, GDPR compliance and trial master file for Biomendex, thereby supporting the collection of clinical data necessary for market access of this medical device.
“This is an exciting time as our team at Biomendex has successfully advanced towards CE marking by launching this pivotal clinical investigation and is navigating the challenges with Aurevia to achieve this significant milestone,” says Biomendex Ltd. CEO Pasi Kankaanpää.
The first site has been opened at Helsinki University Hospital, where also recruiting the first patients is taking place. As the first stage of the investigation proceeds, additional sites will be opened for recruitment.
Biomendex works to enhance tissue technology and manufactures superior medical devices.
Learn more about Biomendex
Notice about a change in some of our email addresses
How do you shape regulatory complexity into strategic clarity?
Fast track for mononational clinical trial applications in Sweden
Upcoming webinar: what IVDR Article 5(5) means for your lab
